Commercial stage biopharmaceutical company with a transdermal drug delivery platform
Corium (NASDAQ: CORI) is a leader in transdermal delivery systems and related technologies through its platform based on two differentiated, proprietary technologies – MicroCor (large molecules, or biologics, including vaccines, peptides, and proteins) and Corplex (small molecules that are difficult to delivery in transdermal dosage form) – for transporting drugs through the skin for absorption into the body. The company has a fully functioning GMP production operation in Grand Rapids, MI and has completed development through various stages of FDA filings for several therapeutic products for its partners, with over 180 patents issued, published, and pending related to microstructures, polymers, adhesives, transdermal and other drug delivery technologies. Corium’s impressive track record of proven development and commercialization capabilities is demonstrated by its partnerships with P&G, Par Pharmaceutical, Teva Pharmaceuticals USA, Agile Therapeutics, amongst others.
Corium (NASDAQ: CORI) is a leader in transdermal delivery systems and related technologies through its platform based on two differentiated, proprietary technologies – MicroCor (large molecules, or biologics, including vaccines, peptides, and proteins) and Corplex (small molecules that are difficult to delivery in transdermal dosage form) – for transporting drugs through the skin for absorption into the body. The company has a fully functioning GMP production operation in Grand Rapids, MI and has completed development through various stages of FDA filings for several therapeutic products for its partners, with over 180 patents issued, published, and pending related to microstructures, polymers, adhesives, transdermal and other drug delivery technologies. Corium’s impressive track record of proven development and commercialization capabilities is demonstrated by its partnerships with P&G, Par Pharmaceutical, Teva Pharmaceuticals USA, Agile Therapeutics, amongst others.
Location: United States, California, Menlo Park
Investors 2
| Date | Name | Website |
| - | EW Healthc... | ewhealthca... |
| - | CRG | crglp.com |
Mentions in press and media 8
| Date | Title | Description |
| 27.11.2018 | Gurnet Point Capital Completes Tender Offer for Corium International, Transaction Valued in Excess of $500 Million | Nov 27 2018 CAMBRIDGE, Mass.—(BUSINESS WIRE)—Gurnet Point Capital (“Gurnet Point”), a private investment firm focused on the healthcare and life sciences sectors, announced today that it has completed the previously announced tender offer ... |
| 11.10.2018 | Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares | Oct 11 2018 Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex Donepezil MENLO PARK, Californi... |
| 22.02.2016 | Corium Announces Positive Topline Results from Phase 1 Clinical Study | Feb 22 2016 MENLO PARK, California—Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced posi... |
| 05.08.2015 | Corium Prices Follow-On Offering of Common Stock | Aug 05 2015 MENLO PARK, California (GLOBE NEWSWIRE)—Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, tod... |
| 29.07.2015 | Corium Reports Third Quarter Fiscal 2015 Financial Results | Jul 29 2015 MENLO PARK, California—Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced una... |
| 27.07.2015 | Corium Co-Founder Dr. Gary W. Cleary Honored with Controlled Release Society Founders Award | Jul 27 2015 MENLO PARK, California—Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today tha... |
| 03.02.2011 | Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors | Feb 03 2011 MENLO PARK, California – Corium International, Inc., a privately-held advanced transdermal drug delivery company, today announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the Board of Directors. Dr. Ch... |
| 27.09.2007 | Life sciences briefing: Thursday, Sept. 27, 2007 | Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium International, New Ortho Polymers, Osprey Pharmaceuticals, Othera Pharmaceuticals, StrataGent Life Sciences Corium acquires Stratagent, raises $25.1... |